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ABSTRACT
Acquired hemophilia A (AHA) is a rare disorder that results from the presence of autoantibodies against the clotting 
factor VIII (FVIII) causing hemorrhagic disorders. This entity is mostly associated with autoimmune diseases, pregnancy, 
the postpartum period, drugs and malignancy. Among the solid cancers, prostate neoplasm is the most common cause of 
AHA. The management of AHA involves the control of active bleeding and the use of specific therapies to eliminate the 
inhibitor. The authors describe the case of an 87-year-old man with prostate cancer who developed a bleeding disorder 
5 years after the cancer diagnosis. Treatment with prednisone did not reach a satisfactory clinical response, which was 
only achieved with the association of azathioprine. The patient became asymptomatic with no further bleeding episodes, 
but developed a fatal sepsis after 3 months of treatment with these immunosuppressive agents.
Keywords 
Factor 8 deficiency, acquired; Prostatic Neoplasm; Hemorrhage.
INTRODUCTION
Acquired hemophilia A (AHA) is a rare and 
potentially life-threatening hemorrhagic disorder 
caused by the development of autoantibodies directed 
against the coagulation factor VIII (FVIII).1
In approximately half of the cases, no underlying 
condition potentially related to the development of 
AHA can be identified; therefore, these cases are called 
idiopathic AHA.2 In the remaining cases, the most 
commonly associated conditions are: autoimmune 
disorders, the postpartum period, and malignancy, 
present in approximately 10% of patients.3
Abnormal bleeding occurs in approximately 
10% of patients with solid tumors, and in a higher 
proportion of patients with hematologic malignancies.4 
The potential causes of new onset bleeding in patients 
with malignancy include pre-existing mild congenital 
hemophilia and other coagulation factor deficiencies, 
congenital von Willebrand disease, thrombocytopenia, 
neoplastic bone marrow invasion, chemo-radiation 
side-effects, decreased synthesis of coagulation factors 
due to liver dysfunction, disseminated intravascular 
coagulation, and acquired inhibitors against blood 
clotting factors.4 Moreover, since thromboembolic 
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events are very common in patients with advanced 
malignancies, a significant proportion of patients 
may develop bleeding events related to the use of 
prophylactic or therapeutic anti-thrombotic therapy.
The presence of cancer in AHA portends a worse 
outcome compared to patients who do not have an 
associated cancer.4,5 In the present report, we describe 
a rare event of malignancy-associated AHA.
CASE REPORT
An 87-year-old man was referred to the oncologic 
center because of an abnormal prostate-specific 
antigen (PSA) determination, which was tested during 
a routine evaluation. His physical examination was 
unremarkable except for an abnormal digital rectal 
examination, which demonstrated a firm prostate 
gland suspicious for prostate cancer. A prostatic 
biopsy was performed, which revealed a Gleason 
score 7 (3 + 4) adenocarcinoma. A radionuclide bone 
scan demonstrated an abnormal uptake in several 
ribs consistent with bone metastasis. His past medical 
history included hypertension and chronic kidney 
disease with an estimated creatinine clearance of 
20 mL/min. His medications included amlodipine 
and hydrochlorothiazide and he did not take any 
anticoagulants or non-steroidal anti-inflammatory 
drugs. There was no personal or familial history of 
abnormal bleeding, and no altered blood clotting test 
was present at diagnosis.
Two months after the prostate cancer diagnosis, 
surgical castration was performed, which was followed 
by a significant decrease of the PSA determinations 
with a nadir of 9 ng/dL. After 2 years, the patient 
developed castration-resistant disease and the PSA 
levels rose again. At that time, the patient started on 
a peripheral anti-androgen blockade with bicalutamide 
with a decline in transient PSA determinations followed 
by a rising PSA within 12 months. Subsequently, the 
patient received second-line therapy with prednisone 
5 mg twice daily, leading to stabilization of the PSA 
levels at around 20.0 ng/dL.
Five years after the prostate cancer diagnosis, 
the patient developed gross hematuria, back pain, 
and spontaneous skin hematomas, and was admitted 
to the emergency department with severe anemia 
(hemoglobin determination of 4.8 g/dL (reference 
value [RV]: 13.0–18.0 g/dL) requiring red-blood-cell 
transfusion. Coagulation tests revealed a prothrombin 
time (PT) of 14.7 seconds and 83% of activity 
(RV: > 70%); active partial thromboplastin time (aPTT) 
of 97.7seconds (RV: 23–31 sec) and a fibrinogen level 
of 406 mg/dL (RV: 220–496 mg/dL). The active partial 
thromboplastin time was not corrected after mixing 
study neither lupus anticoagulants were identified. The 
patient’s liver function tests were normal.
The clinical scenario of abnormal bleeding 
associated with these laboratory abnormalities led to 
the hypothesis of the presence of an inhibitor of the 
coagulation factor. The diagnosis of AHA was confirmed 
with the quantification of FVIII < 1% (RV: 50–150%) 
and the identification of the FVIII inhibitor that was 
quantified as 864 Bethesda Units (BU) (RV: < 0.6 BU). 
The PSA level was stable and a computerized tomography 
(CT) scan demonstrated no signs of new metastasis 
or evidence of cancer progression, but revealed an 
iliopsoas hematoma (Figure 1A and 1B).
Figure 1. Abdominal CT. Axial (A) and coronal (B) planes showing volumetric enlargement of the left iliopsoas 
muscle (white arrows).
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Once the diagnosis was confirmed, the treatment 
was initiated with prednisone 1 mg/kg per day without 
improvement during the first 48 hours. Therefore, 
a daily dose of 100 mg of azathioprine was added. 
On the following day, the hematuria ceased, the 
hemoglobin level remained stable, and no signs of new 
skin hematomas were observed. Homeostatic agents 
were not necessary at any time during the patient’s 
hospitalization.
On the following days, a new CT study showed 
no further enlargement of the iliopsoas hematoma 
(Figure 2A and 2B) and the hematoma-associated back 
pain improved. The patient became asymptomatic and 
was discharged after 17 days of hospitalization.
Over the following 3 months after hospital 
discharge, the patient demonstrated a progressive 
fall of the inhibitor titles (lowest quantification 
of 7.6 UBTH) and an increase of the coagulation 
FVIII levels (28%). Furthermore, no other hemorrhage 
phenomenon was noted on follow-up. However, after 
3 months, the patient was admitted to the Intensive 
Care Unit with the diagnosis of pneumonia, and died 
due to septic shock.
DISCUSSION
AHA is a rare disease caused by anti-FVII I 
autoantibodies. The incidence of AHA is 1.3–1.5 cases 
per million per year and up to 85% involve the elderly 
population.6,7
The most common etiological factors associated 
with AHA are autoimmune disease, such as systemic 
lupus erythematous, rheumatoid arthritis, or Sjögrens 
syndrome, pregnancy, the postpartum period, 
drug-associated AHA, and malignancy.4,8 However, in 
approximately 50% of patients, no underlying disorder 
is detected.2
Underlying malignancy is present in about 10% of 
the cases of AHA.4 Among the solid cancers, prostate 
cancer is the most common cause of AHA followed 
by lung cancer.3,4 In the majority of cases, malignancy 
predates or is diagnosed concurrently with the bleeding 
disorder.4
The clinical manifestations of AHA are different 
from those observed in patients with congenital 
hemophi l ia .  Whereas congenita l  hemophi l ia 
typically presents hemarthrosis in the younger male 
population, acquired hemophilia frequently presents 
with mucocutaneous or soft tissue bleeding in the 
elderly.4 Life-threatening hemorrhage occurs in about 
9–22% of this population7,9 and the high mortality 
rate of 10–33% has been reported, which is due to 
spontaneous bleeding in most cases, or is related to 
associated conditions, such as cancer.6
The clinical presentation of cancer-associated 
AHA is similar to that observed in acquired AHA 
without any underlying malignancy, except for more 
genitourinary hemorrhage in the former, which is 
probably due to the predominance of prostate cancer 
among those cases.3 In 2001, Sallah and Wan3 reported 
that the most common sites of bleeding in patients 
with malignancy-associated AHA were soft tissue, 
hematuria, and skin.
No specific characteristic of the neoplasia, such as 
disseminated disease or histologic type, are associated 
with the development of AHA, and the reappearance 
Figure 2. CT scan. Axial (A) and coronal (B) planes showing a mild decrease in the size of the left iliopsoas muscle 
hematoma (white arrows).
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of the FVIII inhibitors is not associated with the 
neoplasm relapse.10
Due to the relative rarity of this condition, 
the diagnosis is often difficult and delayed.4 Initial 
testing usually reveals an isolated prolonged aPTT 
with a normal PT and platelet count, which are 
associated with a reduced level of FVIII.4 Importantly, 
the use of warfarin, heparin, and an abnormal liver 
function must be ruled out as alternative diagnoses.6 
In AHA, the aPTT test after mixing study typically 
fails to normalize and can be misinterpreted as 
being related to a lupus inhibitor. Therefore, the 
International Guidelines for the diagnosis of AHA11 
recommend ruling out lupus anticoagulants by a 
specific test.6 In order to demonstrate the presence of 
the inhibitor, the Bethesda assay for the quantification 
of the inhibitor must be performed in these patients.6,9,11
The management of AHA involves the control 
of active bleeding and specific therapies to eliminate 
the FVIII-inhibitor.6 The bleeding management can be 
done with homeostatic agents such as the recombinant 
FVIIa (rFVIIA), the activated prothrombin complex 
concentrate (aPCC), the 1-deamino-8-D-arginine 
vasopressin (DDAVP), and FVIII concentrates. In most 
cases, rFVIIa and aPCC have greater efficacy than 
human FVIII or DDAVP in achieving hemostasia, and 
must be the treatment of choice.4,11-13
The international recommendations for the 
diagnosis and treatment of patients with AHA highlight 
the definition of treatment failure as: hemoglobin 
decrease despite red-blood-cell replacement, increasing 
dimensions of internal bleeding on imaging studies, 
evidence of continuous bleeding after 48 hours of 
appropriate treatment, bleeding on a new site, and 
increasing pain associated with hematoma despite 
treatment.11
The deletion of the FVII I- inhibitor may be 
achieved with corticosteroids alone or corticosteroids 
associated with other immunosuppressant agents, 
such as cyclophosphamide or different combinations 
of azathioprine, rituximab, and cyclosporine A.6,11,14 
Corticosteroids are the first-line therapy and may 
draw a complete remission in about 48% of patients, 
defined as undetectable FVIII-inhibitor levels and an 
FVIII higher than 70 IU/dL after the discontinuation 
of immunosuppressive therapy.14 The combination 
with cyclophosphamide not only increases the overall 
response to 60–100%, but also may be associated 
with adverse effects, such as a higher incidence of 
infections.8 In 2007, Collins et al.7 did not find any 
difference in efficacy comparing corticosteroids alone 
with corticoids combined with cytotoxic agents, 
showing a complete remission rate of approximately 
70%. This study also reported a rate of 33% of sepsis, 
which contributed to death in 11% of the cases.7 
Others have demonstrated that the treatment of the 
underlying cancer with chemotherapy, surgery, or 
hormonal manipulation led to the disappearance of 
the inhibitor in 22% of patients. However, it is very 
difficult to speculate the exact role of oncologic therapy 
in this setting, since these results were not confirmed 
by other researchers.3,10
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